Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma.

Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34277756

about

Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice.A disparate subset of double-negative T cells contributes to the outcome of murine fulminant viral hepatitis via effector molecule fibrinogen-like protein 2.Activation of Hepatic Stellate Cells During Liver Carcinogenesis Requires Fibrinogen/Integrin αvβ5 in Zebrafish.

P2860

Q28080245-2BA39BBB-9255-4D90-AA19-9A3995F6470A Q33837289-BF018855-25A6-4399-96C4-EF46C57B2F39 Q36962436-E2C003A8-4079-43B2-B898-7CE53B78CAC1 Q38754395-D1297E58-A827-4A3F-B7F7-90DD27E54378 Q40945718-E3C9D516-755E-4DCA-8C2C-8852025BAF0B Q52591520-59F920EE-F7BF-4DEA-A1B2-26C19910FF5E

P2860

Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34277756

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@ast

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@en

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@nl

type

label

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@ast

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@en

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@nl

prefLabel

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@ast

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@en

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@nl

P1433

Q34277756-61C9A578-3A87-46BB-8398-A6A70E22F5BE

P1476

Q34277756-AA4D875F-6CB3-42DF-A6B5-34ED98322656

P2093

Q34277756-14E19C77-CFB8-41C6-A63D-9E70C4E9CFF6

Q34277756-450D269C-7088-4CD7-A853-782225856740

Q34277756-6C4EF2D7-903E-4512-AC8A-B87E573D5B2A

Q34277756-9F9DB040-B0E6-4713-85E4-7BFD3B8EE099

Q34277756-C73C9F48-FB4D-4E1B-845F-38DF386BB5A8

Q34277756-D8D5313B-4D84-446F-8C6F-C6A9AE0F1486

P2860

Q34277756-116F6185-EA2F-4F7C-91D2-86C2CADA4909

Q34277756-12215292-43BB-4D0D-99F2-DCA6B85DB84E

Q34277756-1296A8AF-2473-4994-8005-3E734AEC0DD3

Q34277756-34408BEE-87EF-4F74-95E5-EF288D01C782

Q34277756-4F241AA1-BC2B-4DF5-870E-2015542F94A7

Q34277756-522BEF28-F506-424C-A652-357E60AC995E

Q34277756-5B5E804D-60EC-4270-89CF-290179AFA73B

Q34277756-613C457E-CBA1-4A53-93E5-68579BE75863

Q34277756-73165922-5D1B-48F8-B999-35A0AAA1F3B7

Q34277756-89E3AEBB-86F1-4049-B088-CE5B3459CFBD

P2888

Q34277756-A88B6A28-4624-4619-9DA6-0BC9017A316E

P304

Q34277756-46F6E64A-C963-495A-8A10-790B4EAB6BD7

P31

Q34277756-BFB37B9C-BD95-4544-8CFB-2A67E8288331

P356

Q34277756-101A29A6-79B1-4CBC-B91D-FA4386361B72

P433

Q34277756-B1AA137D-8897-4A0A-B74C-7766D727C03D

P478

Q34277756-B58012EC-08A3-4CF2-B7D4-66D6C6B5CFB0

P577

Q34277756-303522E0-B111-4487-8C31-A5C9F6293840

P5875

Q34277756-559500AE-502E-43DB-AC25-C68D874C139A

P6179

Q34277756-F4182D6D-91F0-4110-A4F0-0C0A99C87E29

P698

Q34277756-7D44A9AF-4F7E-4E89-8674-F05FB970BD12

P921

Q34277756-7A71C464-FAE0-4DC3-8508-E25215844348

P932

Q34277756-6B7B0BD5-15C9-456B-8261-E36E5C88BBF6

P356

S12072-014-9568-Y

P1433

Hepatology international

P1476

Soluble FGL2, a novel effector ...... with hepatocellular carcinoma.

@en

P2093

Dong Xi

http://www.w3.org/2001/XMLSchema#string

Faxi Wang

http://www.w3.org/2001/XMLSchema#string

Haili Zhou

http://www.w3.org/2001/XMLSchema#string

Qin Ning

http://www.w3.org/2001/XMLSchema#string

Wen Ding

http://www.w3.org/2001/XMLSchema#string

Ying Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Ito cells are liver-resident antigen-presenting cells for activating T cell responses

Inhibition of DNA synthesis in cultured hepatocytes by endotoxin-conditioned medium of activated stellate cells is transforming growth factor-beta and nitric oxide-independent

The global burden of cancer: priorities for prevention.

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.

Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice

The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis

Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).

Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis.

Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance

Hepatic stellate cells promote immunotolerance following orthotopic liver transplantation in rats via induction of T cell apoptosis and regulation of Th2/Th3-like cell cytokine production.

P2888

s12072-014-9568-y

P304

567-575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-014-9568-Y

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266684566

http://www.w3.org/2001/XMLSchema#string

P6179

1040177475

http://www.w3.org/2001/XMLSchema#string

P698

25298849

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

4182595

http://www.w3.org/2001/XMLSchema#string